Pfizer Teminates the Deal to Develop Giroctocogene Fitelparvovec for Hemophilia A with Sangamo Therapeutics
Shots:
- Sangamo regains rights to giroctocogene fitelparvovec (gene therapy for hemophilia A) as Pfizer ends their collaboration (effective Apr 21, 2025) & decids not to file BLA or MAA to pursue commercialization. Sangamo plans to seek a new partner
- The drug is in P-III (AFFINE) trial involving 75 adult males with severe hemophilia A who completed a min 6mos. of routine FVIII replacement prophylaxis. Pfizer (in Jul 2024) reported that the trial met its 1 & 2EPs, showing superiority in reducing mean total ABR (1.24 vs 4.73) from wk.12 to at least 15mos. follow up
- In addition, Sangamo plans to recruit for P-I/II trial of ST-503 for idiopathic small fiber neuropathy by mid-2025 & CTA filing for prion disease program in Q4’25, pending additional funding
Ref: Sangamo Therapeutics | Image: Sangamo Therapeutics
Related News:- Astellas and Sangamo Therapeutics Partner for Administering Genomic Therapies Targeting Neurological Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
